» Articles » PMID: 39604700

Predicting Survival and Recurrence of Lung Ablation Patients Using Deep Learning-Based Automatic Segmentation and Radiomics Analysis

Overview
Date 2024 Nov 28
PMID 39604700
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To predict survival and tumor recurrence following image-guided thermal ablation (IGTA) of lung tumors segmented using a deep learning approach.

Methods And Materials: A total of 113 patients who underwent IGTA for primary and metastatic lung tumors at a single institution between January 1, 2004 and July 14, 2022 were retrospectively identified. A pretrained U-Net model was applied to the dataset of pre- and post-procedure CT scans to segment lung zones. Following lung segmentation, a U-shaped encoder-decoder transformer architecture (UNETR) was trained to segment lung tumors from pre- and post-procedure CT scans, and radiomic features were automatically extracted. These features were input into a support vector machine (SVM)-based survival prediction model trained to assign rank scores to samples based on binary survival or recurrence label and follow-up time. C-index and time-dependent AUC were subsequently calculated to evaluate model performance.

Results: Initial tumor segmentation using UNETR achieved a Dice score of 0.75. Applying a radiomics-based survivability prediction model to the post-procedure scans resulted in a c-index of 0.71 and a time-dependent AUC of 0.75. In contrast, when this model was applied to pre-procedure scans, it achieved a 0.56 for both metrics. For predicting time to recurrence, the radiomics-based model achieved a c-index of 0.65 and a time-dependent AUC of 0.72 on post-procedure imaging. In contrast, when this model was applied to pre-procedure scans, it achieved a 0.54 for both metrics.

Conclusion: Radiomic feature analysis of lung tumors following automatic segmentation by a state-of-the-art transformer-based U-NET may predict survival and recurrence following image-guided thermal ablation of pulmonary malignancies.

Level Of Evidence: Level 3, Retrospective cohort study.

References
1.
Shang Y, Li G, Zhang B, Wu Y, Chen Y, Li C . Image-guided percutaneous ablation for lung malignancies. Front Oncol. 2022; 12:1020296. PMC: 9685331. DOI: 10.3389/fonc.2022.1020296. View

2.
Sugarbaker D . Lung cancer. 6: The case for limited surgical resection in non-small cell lung cancer. Thorax. 2003; 58(7):639-41. PMC: 1746726. DOI: 10.1136/thorax.58.7.639. View

3.
Tselikas L, Garzelli L, Mercier O, Auperin A, Lamrani L, Deschamps F . Radiofrequency ablation versus surgical resection for the treatment of oligometastatic lung disease. Diagn Interv Imaging. 2020; 102(1):19-26. DOI: 10.1016/j.diii.2020.09.006. View

4.
Genshaft S, Suh R, Abtin F, Baerlocher M, Chang A, Dariushnia S . Society of Interventional Radiology Multidisciplinary Position Statement on Percutaneous Ablation of Non-small Cell Lung Cancer and Metastatic Disease to the Lungs: Endorsed by the Canadian Association for Interventional Radiology, the.... J Vasc Interv Radiol. 2021; 32(8):1241.e1-1241.e12. DOI: 10.1016/j.jvir.2021.04.024. View

5.
Wu X, Uhlig J, Blasberg J, Gettinger S, Suh R, Solomon S . Microwave Ablation versus Stereotactic Body Radiotherapy for Stage I Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis. J Vasc Interv Radiol. 2022; 33(8):964-971.e2. DOI: 10.1016/j.jvir.2022.04.019. View